Jun 30, 2015
|
Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015
|
Jun 16, 2015
|
Ardelyx to Present at the 2015 JMP Securities Life Sciences Conference
|
Jun 3, 2015
|
Ardelyx to Raise $77.8 Million in a Private Placement and Announces New Product Candidate for the Treatment of Hyperkalemia to Begin Clinical Development in Mid-2015
|
Jun 3, 2015
|
Ardelyx Regains Worldwide Development and Commercialization Rights for Its Late-Stage Development Candidate, Tenapanor, and Related Portfolio of NHE3 Compounds
|
May 19, 2015
|
Ardelyx Presents Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients at Digestive Disease Week 2015
|
May 12, 2015
|
Ardelyx Reports First Quarter 2015 Financial Results
|
May 5, 2015
|
Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria
|
Apr 20, 2015
|
Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors
|
Mar 13, 2015
|
Ardelyx to Present at the 22nd Annual Future Leaders in the Biotech Industry Conference
|
Feb 25, 2015
|
Ardelyx Reports Fourth Quarter and Full Year 2014 Financial Results
|